Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

IRLAB ramps up for mesdopetam Phase 3 program in Parkinson’s

IRLAB Therapeutics is taking steps in preparation for a Phase 3 clinical program of mesdopetam, an experimental medicine for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The Swedish company is consulting with two advisors, Clintrex and ProPharma Group, to gather the documentation needed to request…